Public Companies
Star Investor Cathie Wood Finally Buys Into Psychedelics
The article Star Investor Cathie Wood Finally Buys Into Psychedelics was originally published on Microdose.
Cathie Wood is an investment superstar. Her…
The article Star Investor Cathie Wood Finally Buys Into Psychedelics was originally published on Microdose.
Cathie Wood is an investment superstar. Her family of ARK Invest funds manages over $60 billion in assets, focusing on innovations like self-driving cars and genomics.
Yesterday her ARK Genomic Revolution ETF bought 83,278 shares of Atai Life Sciences, her first foray into psychedelics.
This is big news. The psychedelic medicine market has been desperate for a shot in the arm, and getting a positive headline that includes Cathie Wood was just what the shaman ordered. And even though the amount invested was relatively small (Atai will be the smallest holding in the ARK ETF), an endorsement from a major kingmaker will go a very long way in legitimizing the sector.
And the results were immediate. Not only was Atai up 14%, but the good news spilled over to others like Compass Pathways and MindMed (MNMD was up 13.4% on Wednesday).
Hopefully, this news signals the beginning of a continued upward trend. Stay tuned for more coverage.
Want to see more about investment funds and ETFs? Check out New Psychedelic ETF Launches on the NASDAQ and A Closer Look at the Actively-Managed PSIL Psychedelic ETF
psychedelics psychedelic etf shares nasdaq mindmed compass atai life sciences atai
Plant Medicine Week 2022: European Psychedelic Clinics and Retreats
Albert Labs Granted Health Canada License
News You Might Have Missed: May 16th, 2022
Atai Gives Business Update, Remains Well Funded
Mid-year Momentum Firing up a Psychedelics Rush
The Daily Hit: May 16, 2022
MindMed Expenses Rise As Company Files $100 Million Offering
Microdose’s Deal Board Helps Democratize Psychedelic Investing
Numinus Receives Health Canada Approval For Psilocybin Treatment
Optimi Health acquires catalog of psychedelic and functional mushroom genetics
-
Psilocybin19 hours agoThe Psychedelics Megatrend Is an Inevitable Boom
-
Public Companies17 hours ago
MindMed Expenses Rise As Company Files $100 Million Offering
-
Markets & Investing19 hours ago
Microdose’s Deal Board Helps Democratize Psychedelic Investing
-
Psilocybin20 hours ago
Optimi Health acquires catalog of psychedelic and functional mushroom genetics
-
Psilocybin13 hours agoCan Ibogaine Treat Emotional Trauma?
-
Psilocybin13 hours agoJourney Colab Looks to Mescaline for Treating Alcohol Use Disorder